Tirzepatide

Tirzepatide 60 mg — Dual GIP/GLP-1 Receptor Agonist for Metabolic Research

Tirzepatide is a synthetic dual receptor agonist designed to activate both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. In preclinical and clinical research, it has been investigated for its effects on glycemic control, body weight, and cardiometabolic risk factors in obesity and type 2 diabetes models.

What It Is

Class: Dual GIP/GLP-1 receptor agonist (incretin mimetic)

Concept: Combines signaling from both incretin pathways to enhance glucose-dependent insulin secretion and modulate appetite, weight, and metabolic markers.

Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Incretin & Islet Biology: GIP receptor activation is studied for potentiation of glucose-dependent insulin secretion and effects on beta-cell function. GLP-1 receptor activation is investigated for improvements in insulin secretion, reduced inappropriate glucagon release, and slowed gastric emptying. Dual agonism is explored for synergistic effects compared to single-receptor incretin agonists.

Body Weight & Metabolic Effects: Acts on central pathways involved in appetite and satiety, with associated reductions in caloric intake. Evaluated for changes in body weight, fat mass, and waist circumference. There is ongoing interest in effects on lipids, liver fat, inflammatory markers, and overall cardiometabolic risk.

Selected Research Highlights

Type 2 Diabetes: Dual GIP/GLP-1 agonism has been studied for robust reductions in HbA1c, fasting glucose, and post-prandial glycemic excursions.

Obesity & Weight Management: Research reports substantial weight loss and favorable changes in body composition under Tirzepatide exposure.

Liver & NAFLD/NASH: Experimental and clinical work has evaluated liver fat content, transaminases, and nonalcoholic fatty-liver disease markers.

Cardiometabolic Parameters: Studies have examined effects on blood pressure, lipids, and other cardiovascular risk factors in high-risk populations.

Chemical & Handling Information

Type: Synthetic dual incretin receptor agonist

Targets: GIP receptor and GLP-1 receptor

Appearance: White to off-white lyophilized powder

Specifications

Glow Pura : Tirzepatide

Amount: 60 mg per vial

Form: Lyophilized powder

Purity: ≥99% (HPLC); COA per lot available

Packaging: Sealed vials suitable for standard laboratory handling

Storage & Stability

Store lyophilized vials in a cool, dry place, protected from light. Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, according to laboratory SOPs.

After reconstitution, store at 2–8 °C for short-term use. For long-term storage, aliquot and freeze at -20 °C or below; avoid repeated freeze–thaw cycles.

Research use only. Not for human or veterinary use.